IL141141A0 - Targeting pharmaceutical agents to injured tissues - Google Patents

Targeting pharmaceutical agents to injured tissues

Info

Publication number
IL141141A0
IL141141A0 IL14114199A IL14114199A IL141141A0 IL 141141 A0 IL141141 A0 IL 141141A0 IL 14114199 A IL14114199 A IL 14114199A IL 14114199 A IL14114199 A IL 14114199A IL 141141 A0 IL141141 A0 IL 141141A0
Authority
IL
Israel
Prior art keywords
binding domain
fusion polypeptide
collagen binding
nucleic acid
acid sequences
Prior art date
Application number
IL14114199A
Other languages
English (en)
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of IL141141A0 publication Critical patent/IL141141A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
IL14114199A 1998-07-31 1999-07-30 Targeting pharmaceutical agents to injured tissues IL141141A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/127,134 US6387663B1 (en) 1998-07-31 1998-07-31 Targeting pharmaceutical agents to injured tissues
PCT/US1999/017297 WO2000006195A1 (en) 1998-07-31 1999-07-30 Targeting pharmaceutical agents to injured tissues

Publications (1)

Publication Number Publication Date
IL141141A0 true IL141141A0 (en) 2002-02-10

Family

ID=22428477

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14114199A IL141141A0 (en) 1998-07-31 1999-07-30 Targeting pharmaceutical agents to injured tissues
IL141141A IL141141A (en) 1998-07-31 2001-01-28 A pooled polypeptide that includes a collagen binding domain and a blood vessel formation regulating domain
IL190793A IL190793A0 (en) 1998-07-31 2008-04-10 A fusion polypeptide comprising a collagen binding domain and an angiogenesis modulating domain

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL141141A IL141141A (en) 1998-07-31 2001-01-28 A pooled polypeptide that includes a collagen binding domain and a blood vessel formation regulating domain
IL190793A IL190793A0 (en) 1998-07-31 2008-04-10 A fusion polypeptide comprising a collagen binding domain and an angiogenesis modulating domain

Country Status (11)

Country Link
US (2) US6387663B1 (ja)
EP (1) EP1100535B1 (ja)
JP (1) JP4564657B2 (ja)
AT (1) ATE467425T1 (ja)
AU (1) AU758483B2 (ja)
CA (1) CA2337979A1 (ja)
DE (1) DE69942365D1 (ja)
ES (1) ES2346275T3 (ja)
IL (3) IL141141A0 (ja)
NZ (1) NZ509804A (ja)
WO (1) WO2000006195A1 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU764520B2 (en) * 1999-07-21 2003-08-21 University Of Southern California Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
ES2283398T3 (es) * 2000-03-15 2007-11-01 Orbusneich Medical, Inc. Recubrimiento que mejora la adherencia de celulas endoteliales.
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
EP1314780A4 (en) * 2000-08-15 2004-07-28 Terumo Corp Collagen-binding hybrid polypeptides
AU2002211561A1 (en) * 2000-10-11 2002-04-22 The Wistar Institute Regulation of human skin healing
ES2186501B1 (es) * 2000-11-23 2006-05-16 Universidad De Malaga Factor de crecimiento fibroblastico basico con un dominio de union especifico a colegeno.
US7217570B2 (en) 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7060684B1 (en) 2002-12-16 2006-06-13 Quijano Rodolfo C Device for treating diabetes and methods thereof
WO2005003317A2 (en) * 2003-07-01 2005-01-13 Regents Of The University Of Minnesota Engineered blood vessels
EP2267030A1 (en) * 2005-08-25 2010-12-29 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
US8802396B2 (en) 2005-12-26 2014-08-12 Yantai Zhenghai Bio-Technology Co., Ltd. Activated collagen scaffold materials and their special fused active restoration factors
CN101505723A (zh) * 2006-06-22 2009-08-12 南佛罗里达大学 胶原支架、具有其的医用植入物以及使用方法
DE102007010306A1 (de) * 2007-02-22 2008-08-28 Eberhard-Karls-Universität Tübingen Universitätsklinikum Bispezifisches Fusionsprotein mit therapeutischem und diagnostischem Potenzial
EP3091075B1 (en) 2007-04-09 2018-06-13 The Board of Trustees of The University of Arkansas Fusion proteins of collagen-binding domain and parathyroid hormone
JP5260976B2 (ja) * 2008-02-08 2013-08-14 東ソー株式会社 血液凝固第ｖｉｉｉ因子ｃ２ドメインタンパク質の製造方法
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN101671396B (zh) * 2008-09-11 2012-07-18 烟台正海生物技术有限公司 与胶原蛋白特异结合的血管内皮生长因子及其应用
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
KR20130055647A (ko) * 2010-07-19 2013-05-28 에프. 호프만-라 로슈 아게 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
WO2012112767A2 (en) * 2011-02-16 2012-08-23 Purdue Research Foundation Collagen-targeted nanoparticles
EP3391899B1 (en) 2011-12-14 2020-07-15 The Board of Trustees of the University of Arkansas Delivery of therapeutic agents by a collagen binding protein
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
US10420820B2 (en) 2014-09-29 2019-09-24 Counterpoint Biomedia LLC Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
CN106188306B (zh) * 2015-05-04 2020-07-24 北京同建再生医学技术有限公司 治疗性重组抗体、其编码基因及应用
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
US10981980B2 (en) 2016-06-15 2021-04-20 Counterpoint Biomedica Llc Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
WO2018057522A1 (en) * 2016-09-20 2018-03-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface
US10913779B2 (en) 2017-01-25 2021-02-09 Counterpoint Biomedica Llc Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
JP7397440B2 (ja) 2017-02-10 2023-12-13 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合薬剤組成物およびその使用方法
CN109125710A (zh) * 2017-06-15 2019-01-04 中国科学院遗传与发育生物学研究所 胶原靶向血管内皮生长因子在陈旧性心肌梗死治疗中的应用
WO2019173829A1 (en) 2018-03-09 2019-09-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Delivering biological drugs to tissues
EP3870598A1 (en) 2018-10-23 2021-09-01 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
US20220281936A1 (en) * 2019-07-25 2022-09-08 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
CN113121700B (zh) * 2019-12-30 2023-06-13 独步吾奇生物医疗科技(江苏)有限公司 与胶原特异结合的重组蛋白、其编码基因及应用
IL297495A (en) 2020-04-22 2022-12-01 Dragonfly Therapeutics Inc Dosing regimen, formulation and manufacturing process for fc fusion heterodimeric proteins
WO2022256568A1 (en) * 2021-06-02 2022-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for localization of growth factors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0255206B1 (en) * 1986-05-30 1995-03-22 The Scripps Research Institute Peptides that inhibit von Willebrand factor binding
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
WO1998044938A1 (en) * 1997-04-10 1998-10-15 University Of Southern California Modified proteins which bind extracellular matrix components
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions

Also Published As

Publication number Publication date
DE69942365D1 (de) 2010-06-24
ATE467425T1 (de) 2010-05-15
JP4564657B2 (ja) 2010-10-20
ES2346275T3 (es) 2010-10-13
AU758483B2 (en) 2003-03-20
WO2000006195A1 (en) 2000-02-10
CA2337979A1 (en) 2000-02-10
EP1100535A4 (en) 2004-12-29
EP1100535A1 (en) 2001-05-23
JP2002521044A (ja) 2002-07-16
AU5328699A (en) 2000-02-21
US6387663B1 (en) 2002-05-14
US20020164719A1 (en) 2002-11-07
IL141141A (en) 2008-07-08
IL190793A0 (en) 2008-11-03
US6955898B2 (en) 2005-10-18
EP1100535B1 (en) 2010-05-12
NZ509804A (en) 2003-07-25

Similar Documents

Publication Publication Date Title
IL141141A0 (en) Targeting pharmaceutical agents to injured tissues
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
IL140700A0 (en) Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
WO1996025947A3 (en) Induction of e-selectin for targetting therapeutic agents
PT698108E (pt) Vectores adenovirais de origem animal e utilizacao em terapia genica
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
WO2001068811A3 (de) Verfahren zur in vitro-herstellung von dreidimensionalem, vitalem knorpel- oder knochengewebe und dessen verwendung als transplantationsmaterial
AU3368497A (en) Human dnase i hyperactive variants
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
ATE382061T1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
EP1223953A4 (en) FUSION POLYPEPTIDES FOR TISSUE GENERATION AND WIND HEALING FOR TARGETED MATRIX USE
ATE127020T1 (de) Pharmazeutische zusammensetzungen mit eierschalenbestandteilen und ihre herstellung und verwendung.
WO2003035688A3 (en) Targeted thrombosis by tissue factor polypeptides
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
IL133172A (en) Diphosphonic acid salts for the treatment of osteoporosis
WO1991003226A3 (en) Pharmaceutical compositions containing aromatic polymers and therapeutic methods using the same
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
MX9800801A (es) Proteina mp52 arg humana.
ATE349521T1 (de) Mit cd40 und traf interagierende proteine
ATE362531T1 (de) Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung
WO2001096398A3 (en) Uncoupling proteins as targets for the treatment of heart failure

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed